F16
Based on 1 Customer Validation
F16 is a mitochondrial permeability transition pore (PTP) modulator with an EC50 of 30 μM in mice. F16 promotes PTP opening, accumulates in cancer cell mitochondria, and induces mitochondrial depolarization, swelling, cristae disruption, outer membrane rupture, ATP depletion, reactive oxygen species (ROS) production, cytochrome c release and mitochondrial uncoupling. F16 induces cell cycle arrest at the G1 (occasionally G2) phase, reduces the phosphotyrosine content of Neu, as well as the levels of phosphorylated PKB/Akt and phosphorylated MAP kinase, downregulates the protein expression levels of Neu and PKB, triggers apoptosis in cells with moderate Bcl-2 expression, and induces necrosis in cells with overexpressed Bcl-2. F16 can be used in research related to breast cancer and gastric cancer.
For research use only. We do not sell to patients.
- Purity : 98.67%
- CAS No.: 36098-33-6
- Formula: C16H15IN2
- Molecular Weight:362.21
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biological Activity
Description
|
PTP 30 μM (EC50) |
PKB |
Akt |
MAP |
Neu |
Bcl-2 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| SGC-7901 | IC50 |
3.45 μM
|
Inhibits SGC-7901 cells growth.
Inhibits SGC-7901 cells growth.
|
29069523 |
| MCF7 | IC50 |
18.99 μM
|
Inhibits mcf-7 cells growth.
Inhibits mcf-7 cells growth.
|
29069523 |
| GES1 | IC50 |
41.79 μM
|
Inhibits GES-1 cells growth.
Inhibits GES-1 cells growth.
|
29069523 |
| HEK293 | IC50 |
38.49 μM
|
Inhibits HEK-293 cells growth.
Inhibits HEK-293 cells growth.
|
29069523 |
In Vitro
F16 (100 nM-15 μM; 36-40 h) selectively inhibits proliferation of EpH4-A6 neu-overexpressing mouse mammary epithelial cells, with partial inhibition observed at concentrations as low as 100 nM[1].
F16 (3 μM; 3-7 days) inhibits proliferation of neu-, v-Ha-ras-, and β-catenin-initiated mouse mammary tumor cell lines and most human breast cancer cell lines[1].
F16 (3 μM; 36 h-3 days) induces cell cycle arrest (primarily G1 arrest) in EpH4-A6 neu-overexpressing mouse mammary epithelial cells and sensitive mouse and human breast tumor cell lines[1].
F16 (24 h) induces S phase cell cycle arrest in SGC-7901 cells after 24 h of incubation[3].
F16 (3 μM; 15-72 h) induces apoptosis in EpH4-A6 neu-overexpressing mouse mammary epithelial cells, characterized by oligonucleosomal DNA fragmentation, Annexin V positivity, and cytochrome c release, but does not induce apoptosis in EpH4-EV control cells[1].
F16 (0.3-3 μM; 48 h) induces oligonucleosomal DNA fragmentation (apoptosis) in apoptosis-sensitive EpH4-A6 and SMF cells, but not in apoptosis-resistant EpH4, Bcl-2-overexpressing EpH4-A6.C13, EpH4-A6.C18, SMF-Bcl-2, or NF324-1C cells[2].
F16 (3 μM; 18-36 h) induces cytochrome c release (an apoptotic marker) in apoptosis-sensitive EpH4-A6 cells within 18 h, but not in apoptosis-resistant Bcl-2-overexpressing EpH4-A6.C13 and EpH4-A6.C18 cells, where delayed cytochrome c localization changes are associated with mitochondrial breakdown rather than apoptosis[2].
F16 (3 μM; 24 h) induces caspase-3 activation (an apoptotic marker) in apoptosis-sensitive EpH4-A6 and SMF cells, but not in apoptosis-resistant Bcl-2-overexpressing EpH4-A6.C13, EpH4-A6.C18, SMF-Bcl-2, or NF324-1C cells[2].
F16 (Various concentrations; 24 h) induces apoptosis in SGC-7901 cells in a concentration-dependent manner after 24 h of incubation[3].
F16 (3 μM; 2-24 h) accumulates selectively in mitochondria of sensitive mouse and human mammary tumor/transformed epithelial cell lines, but not in resistant normal or tumor cell lines[1].
F16 (3 μM; 1 h) accumulation in mitochondria is driven and retained by the mitochondrial transmembrane potential (ΔΨm), and lack of accumulation in resistant cell lines is not mediated by MDR-1 or MRP-1 pumps[1].
F16 (1 μM; 1 h) does not alter accumulation in EpH4-A6 cells due to Bcl-2 overexpression, with F16-sensitive cell lines showing higher mitochondrial accumulation than F16-resistant cell lines[2].
F16 (3-50 μM; 15-72 h) compromises mitochondrial structure and function in sensitive cells, causing swelling, ATP depletion, superoxide production, permeability transition pore opening, and altered respiration, leading to cytotoxicity[1].
F16 (3 μM; 24-48 h) downregulates Neu-dependent signaling in EpH4-A6 neu-overexpressing mouse mammary epithelial cells, reducing phosphorylation of Neu, PKB, and MAPK, and decreasing Neu and PKB protein levels[1].
F16 (3 μM; 24-96 h) induces a time-dependent reduction in cell number in apoptosis-sensitive EpH4-A6 and SMF cells, as well as apoptosis-resistant Bcl-2-overexpressing EpH4-A6.C13, EpH4-A6.C18, SMF-Bcl-2, and NF324-1C cells, with a 3 μM concentration causing up to 32-fold reduction in cell number over 96 h in EpH4-A6 cells[2].
F16 (3 μM; 24-48 h) induces apoptosis in EpH4-A6 cells and necrosis in Bcl-2-overexpressing EpH4-A6.C13 and EpH4-A6.C18 cells; caspase inhibition reduces F16-induced death in EpH4-A6 cells, while buffering ATP levels and neutralizing superoxide reduces necrotic death in Bcl-2-overexpressing cells[2].
F16 (3 μM; 48 h) induces apoptotic morphological changes in EpH4-A6 cells and necrotic morphological changes in Bcl-2-overexpressing EpH4-A6.C13 cells after 48 h of incubation[2].
F16 (3 μM; 15-48 h) induces a time-dependent decrease in cellular ATP levels in both apoptosis-sensitive EpH4-A6 and SMF cells, and apoptosis-resistant Bcl-2-overexpressing EpH4-A6.C13, EpH4-A6.C18, SMF-Bcl-2, and NF324-1C cells, with a 50-60% reduction in ATP levels observed after treatment in SMF-derived and NF324-1C cells[2].
F16 (48 h) has its cytotoxicity on SGC-7901 cells almost completely reversed by ATP pre-treatment 0.5 h before F16, indicating that decreased intracellular ATP availability is a major factor in F16-mediated cytotoxicity[3].
F16 (3 μM; 15-72 h) induces a time-dependent increase in superoxide anion levels in apoptosis-sensitive EpH4-A6 cells and apoptosis-resistant Bcl-2-overexpressing EpH4-A6.C13 and EpH4-A6.C18 cells, but not in F16-resistant EpH4-EV cells[2].
F16 (48 h) potently inhibits proliferation of SGC-7901 and MCF-7 cancer cells with over 10-fold selectivity for SGC-7901 cells over non-tumor GES-1 cells[3].
F16 (48 h) increases intracellular ROS levels in SGC-7901 cells after 48 h of incubation, with partial reversal by pre-treatment with reductants[3].
F16 (3 µM; 24 h) selectively accumulates in the mitochondria of SGC-7901 cells after 24 h of incubation at 3 µM[3].
F16 (48 h) reduces intracellular ATP levels in SGC-7901 cells after 48 h of incubation, with no additional effect at higher concentrations[3].
F16 (10 µM; higher concentrations) induces dose-dependent structural damage to isolated rat liver mitochondria, including swelling at 10 µM and membrane rupture at higher concentrations[3].
F16 enhances H+ and K+ permeabilization of the inner membrane of isolated rat liver mitochondria in a concentration-dependent manner[3].
F16 immediately increases the membrane fluidity of isolated rat liver mitochondria, as measured by reduced fluorescence anisotropy of HP-labeled mitochondria[3].
F16 (75 µM) increases state 4 oxygen consumption rate of isolated rat liver mitochondria in a dose-dependent manner, with a 3-fold increase at 75 µM, indicating an uncoupling effect[3].
F16 (20 µM) increases the metabolic thermogenic output of isolated rat liver mitochondria at 20 µM, consistent with an uncoupling effect on oxidative phosphorylation[3].
F16 causes a concentration-dependent decrease in mitochondrial membrane potential (ΔΨm) in isolated rat liver mitochondria, which is mediated by mitochondrial permeability transition (MPT)[3].
F16 (1 h) induces concentration-dependent release of cytochrome c from isolated rat liver mitochondria after 1 h of incubation at 4 °C[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:EpH4-A6 neu-overexpressing mouse mammary epithelial cells, EpH4-EV control mouse mammary epithelial cells
-
Concentration:10-15 μM; 1 μM; 100 nM
-
Incubation Time:36-40 h; (secondary screen, no time specified); (dose-response assay, no time specified)
-
Result:Selectively inhibited BrdU incorporation in EpH4-A6 cells relative to control cells at 10-15 μM.
Partially inhibited BrdU incorporation in EpH4-A6 cells at 1 μM.
Showed partial inhibition in a dose-response format at 100 nM.
-
Cell Line:neu-, v-Ha-ras-, β-catenin-, c-myc-initiated mouse tumor cell lines, human breast cancer cell lines
-
Concentration:3 μM
-
Incubation Time:3 days; 7 days
-
Result:Reduced cell number by 2-5 fold at 3 days and 10-40 fold at 7 days in neu- or v-Ha-ras-initiated mouse mammary tumor cell lines.
Reduced cell number by 2-4 fold in β-catenin-initiated mouse mammary tumor cell lines.
Showed no effect on c-myc-initiated mouse mammary tumor cell lines and v-Ha-ras-initiated mouse fibrosarcoma cell lines.
Inhibited proliferation in 8 of 10 human breast cancer cell lines, with no effect on MDA-MB-231 and MDA-MB-435.
-
Cell Line:EpH4-A6 neu-overexpressing mouse mammary epithelial cells, EpH4-EV control cells, sensitive mouse tumor cell lines, sensitive human breast cancer cell lines
-
Concentration:3 μM
-
Incubation Time:36 h (mouse cells); 3 days (human cells)
-
Result:Caused a dramatic decrease in S-phase cells and an increase in G1-phase cells in EpH4-A6 cells.
Induced similar decreases in S-phase cells in sensitive mouse tumor and human breast cancer cell lines, with most showing G1 arrest and a few showing both G1 and G2 arrest.
Caused no significant changes in EpH4-EV control cells.
-
Cell Line:EpH4-A6 neu-overexpressing mouse mammary epithelial cells, EpH4-EV control cells
-
Concentration:3 μM
-
Incubation Time:48, 60, 72 h (DNA fragmentation); 24, 48, 72 h (Annexin V/7-AAD staining); 15, 24, 48 h (cytochrome c detection)
-
Result:Induced oligonucleosomal DNA fragmentation in EpH4-A6 cells after 48, 60, and 72 h, with no fragmentation in EpH4-EV cells.
Triggered early apoptosis in a subpopulation of EpH4-A6 cells after 24 h, with increased late apoptosis or cell death at longer incubation times; no significant apoptosis in EpH4-EV cells.
Induced early cytochrome c release in EpH4-A6 cells, with loss of punctate mitochondrial staining and appearance of diffuse cytosolic staining.
-
Cell Line:EpH4-A6 neu-overexpressing mouse mammary epithelial cells, EpH4-EV control cells
-
Concentration:3 μM
-
Incubation Time:24, 48 h
-
Result:Decreased phosphotyrosine content of Neu, phosphorylated PKB, and phosphorylated MAPK in EpH4-A6 cells.
Reduced Neu and PKB protein levels in EpH4-A6 cells.
Left MAPK and β-actin levels unchanged in EpH4-A6 cells.
Caused no significant changes in EpH4-EV cells.
-
Cell Line:mouse mammary epithelial EpH4-A6 cells, Bcl-2-overexpressing EpH4-A6.C13 cells, Bcl-2-overexpressing EpH4-A6.C18 cells, mouse mammary adenocarcinoma SMF cells, Bcl-2-overexpressing SMF cells, mouse mammary tumor NF324-1C cells
-
Concentration:3 μM
-
Incubation Time:24 h, 48 h, 96 h
-
Result:Reduced EpH4-A6 cell number by 9.5-fold after 24 h and 32-fold after 96 h.
Reduced EpH4-A6.C13 cell number by 5-fold after 24 h and 20-fold after 96 h.
Reduced EpH4-A6.C18 cell number by 4.2-fold after 24 h and 19-fold after 96 h.
Reduced SMF cell number by 6.4-fold after 48 h.
Reduced Bcl-2-overexpressing SMF cell number by 3.6-fold after 48 h.
Reduced NF324-1C cell number by 2.9-fold after 48 h.
-
Cell Line:mouse mammary epithelial EpH4-A6 cells, Bcl-2-overexpressing EpH4-A6.C13 cells, Bcl-2-overexpressing EpH4-A6.C18 cells
-
Concentration:3 μM; 50 μM zVAD-fmk (Z-VAD-FMK) (HY-16658B) (co-incubated with F16); 28 mM Glucose (D-Glucose) (HY-B0389) (co-incubated with F16); 1 mM Tiron (HY-D0261) (co-incubated with F16)
-
Incubation Time:24 h, 48 h
-
Result:Induced an annexin V positive/7-AAD negative apoptotic population in EpH4-A6 cells.
Induced an annexin V negative/7-AAD positive necrotic population in Bcl-2-overexpressing EpH4-A6.C13 and EpH4-A6.C18 cells.
Caused 22% cell death in EpH4-A6 cells after 24 h, which was reduced to 11% with zVAD-fmk.
Caused 46% cell death in EpH4-A6 cells after 48 h, which was reduced to 28% with zVAD-fmk.
Caused 12% cell death in EpH4-A6.C13 cells after 24 h, which was reduced to 3% with zVAD-fmk plus glucose plus Tiron.
Caused 36% cell death in EpH4-A6.C13 cells after 48 h, which was reduced to 15% with zVAD-fmk plus glucose plus Tiron.
-
Cell Line:mouse mammary epithelial EpH4-A6 cells, Bcl-2-overexpressing EpH4-A6.C13 cells, Bcl-2-overexpressing EpH4-A6.C18 cells, mouse mammary adenocarcinoma SMF cells, Bcl-2-overexpressing SMF cells, mouse mammary tumor NF324-1C cells
-
Concentration:3 μM
-
Incubation Time:24 h
-
Result:Induced appearance of the cleaved (18 kDa) active form of caspase-3 in EpH4-A6 and SMF cells.
Showed no detectable cleaved caspase-3 in EpH4-A6.C13, EpH4-A6.C18, SMF-Bcl-2, or NF324-1C cells.
-
Cell Line:human gastric carcinoma (SGC-7901)
-
Concentration:3 µM
-
Incubation Time:24 h
-
Result:Showed strong overlap with MitoTracker® Red CM-H2XRos fluorescence, indicating selective accumulation in mitochondria.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude mice[1]
-
Dosage:20 mg/kg
-
Administration:i.p.
-
Result:Retarded the growth of subcutaneous tumors derived from EpH4-A6 cells.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 36098-33-6
-
Appearance Solid
-
Molecular Weight 362.21
-
Formula C16H15IN2
-
Color Yellow to orange
-
SMILES
C[N+]1=CC=C(/C=C/C2=CNC3=C2C=CC=C3)C=C1.[I-]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
In Vitro:
DMSO : ≥ 31 mg/mL (85.59 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 1 mg/mL (2.76 mM; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Mitochondrial membrane-potential fluorescent assay
Mitochondrial membrane potential fluorescent assays estimate ΔΨm in living cells using lipophilic cationic dyes such as TMRM, TMRE, rhodamine 123, and JC-1, which accumulate in mitochondria according to membrane polarization; loss of signal after FCCP or CCCP treatment is interpreted as mitochondrial depolarization. TMRM/TMRE and rhodamine 123 are commonly used for semi-quantitative live-cell microscopy or flow cytometry, while JC-1 can report a shift from red aggregate fluorescence to green monomer fluorescence during depolarization; interpretation requires controls because dye concentration, quenching mode, cell type, dye efflux, and mitochondrial mass can affect fluorescence independently of ΔΨm.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Protocol For Protein Expression And Purification
Recombinant protein expression in Escherichia coli followed by purification of a His-tagged soluble protein by immobilized metal affinity chromatography (IMAC), with optional MBP fusion and TEV tag removal when the construct includes these elements. The biological readout is production of the encoded target protein, detected as an inducible band at the expected molecular mass by SDS-PAGE and quantified by total protein assay or chromatographic absorbance; the purification readout is enrichment of the target protein in elution fractions after selective binding of polyhistidine residues to immobilized Ni2+/metal-chelate resin and elution by imidazole-containing buffer. Expression is driven by an inducible bacterial expression system, commonly T7/lac-based, in which IPTG or lactose/auto-induction activates transcription and translation of the cloned gene; lower induction temperature, lower inducer concentration, induction timing, and solubility-enhancing fusion tags can influence the frac
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Transepithelial/transendothelial electrical resistance assay
TEER measures electrical resistance across epithelial or endothelial monolayers cultured on permeable supports, and the readout reflects ionic conductance through the cell barrier, especially the paracellular pathway regulated by junctional integrity. TEER can be measured without destroying the monolayer and is commonly used before or during transport, permeability, barrier-disruption, and barrier-maturation experiments. TEER values are influenced by biological maturation and technical conditions; reported factors include temperature, medium formulation, passage number, electrode geometry, membrane properties, and junctional length during early monolayer maturation. Therefore, TEER should be interpreted with blank-insert subtraction, area normalization, repeated readings, and, when possible, orthogonal barrier readouts such as FITC-dextran flux or tight-junction staining.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Purity & Documentation
-
Data Sheet (307 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Fantin VR, et al. A novel mitochondriotoxic small molecule that selectively inhibits tumor cell growth. Cancer cell. 2002 Jul;2(1):29-42. [Content Brief]
[2]. Fantin VR, et al. F16, a mitochondriotoxic compound, triggers apoptosis or necrosis depending on the genetic background of the target carcinoma cell. Cancer research. 2004 Jan 01;64(1):329-36. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 2.7608 mL | 13.8041 mL | 27.6083 mL | 69.0207 mL |
| DMSO | 5 mM | 0.5522 mL | 2.7608 mL | 5.5217 mL | 13.8041 mL |
| 10 mM | 0.2761 mL | 1.3804 mL | 2.7608 mL | 6.9021 mL | |
| 15 mM | 0.1841 mL | 0.9203 mL | 1.8406 mL | 4.6014 mL | |
| 20 mM | 0.1380 mL | 0.6902 mL | 1.3804 mL | 3.4510 mL | |
| 25 mM | 0.1104 mL | 0.5522 mL | 1.1043 mL | 2.7608 mL | |
| 30 mM | 0.0920 mL | 0.4601 mL | 0.9203 mL | 2.3007 mL | |
| 40 mM | 0.0690 mL | 0.3451 mL | 0.6902 mL | 1.7255 mL | |
| 50 mM | 0.0552 mL | 0.2761 mL | 0.5522 mL | 1.3804 mL | |
| 60 mM | 0.0460 mL | 0.2301 mL | 0.4601 mL | 1.1503 mL | |
| 80 mM | 0.0345 mL | 0.1726 mL | 0.3451 mL | 0.8628 mL |
Keywords
- F16
- 36098-33-6
- F 16
- F-16
- Mitochondrial Metabolism
- Reactive Oxygen Species (ROS)
- Akt
- p38 MAPK
- Bcl-2 Family
- Apoptosis
- Bcl-2
- carcinoma cell mitochondria
- MAP kinase
- normal mammary epithelial cells
- human breast cancer cells
- PKB/Akt
- nude mice
- mitochondrial permeability transition pore
- Neu
- EpH4-A6 neu-overexpressing mouse mammary epithelial cells
- Inhibitor
- inhibitor
- inhibit